Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 33,356 shares, an increase of 593.2% from the August 15th total of 4,812 shares. Currently, 3.3% of the company’s shares are short sold. Based on an average daily trading volume, of 1,671,352 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned about 14.71% of Biodexa Pharmaceuticals at the end of the most recent reporting period. 17.51% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 18th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biodexa Pharmaceuticals currently has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

Shares of BDRX traded up $0.64 during trading hours on Friday, hitting $1.30. The stock had a trading volume of 141,427,163 shares, compared to its average volume of 1,018,600. Biodexa Pharmaceuticals has a 1-year low of $0.61 and a 1-year high of $59.40. The firm has a 50 day simple moving average of $1.52 and a 200-day simple moving average of $2.90.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.